BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 7961285)

  • 21. Profile of intracytoplasmic lysozyme in normal tissues, myeloproliferative disorders, hairy cell leukemia, and other pathologic processes. An immunoperoxidase study of paraffin sections and smears.
    Pinkus GS; Said JW
    Am J Pathol; 1977 Nov; 89(2):351-66. PubMed ID: 335890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [An integrated overview of the pathology of the hematopoietic pluripotential germ cell].
    Sánchez Fayos J
    Rev Clin Esp; 1986 Apr; 178(7):347-53. PubMed ID: 3526426
    [No Abstract]   [Full Text] [Related]  

  • 23. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic factors in myelodysplastic and myeloproliferative types of chronic myelomonocytic leukemia: a retrospective analysis of 83 patients from a single institution.
    Breccia M; Latagliata R; Mengarelli A; Biondo F; Mandelli F; Alimena G
    Haematologica; 2004 Jul; 89(7):866-8. PubMed ID: 15257942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myelodysplastic and myeloproliferative disorders in children.
    Hasle H
    Curr Opin Pediatr; 2007 Feb; 19(1):1-8. PubMed ID: 17224655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnosis and classification of the acute leukemias: recent advances and controversial issues.
    Taylor CG; Stasi R; Bastianelli C; Venditti A; Del Poeta G; Amadori S; Sargent J
    Hematopathol Mol Hematol; 1996; 10(1-2):1-38. PubMed ID: 8792146
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic problems in follow-up bone marrow biopsies of patients treated for acute and chronic leukaemias and MDS.
    Dirnhofer S; Went P; Tichelli A
    Pathobiology; 2007; 74(2):115-20. PubMed ID: 17587882
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of two new classifications for pediatric myelodysplastic and myeloproliferative disorders.
    Occhipinti E; Correa H; Yu L; Craver R
    Pediatr Blood Cancer; 2005 Mar; 44(3):240-4. PubMed ID: 15368549
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical, hematological and histomorphological profile of myelodysplastic syndrome.
    Nigam S; Rani S; Singh T; Gupta S; Rakheja D; Gaiha M
    J Assoc Physicians India; 2001 Apr; 49():430-4. PubMed ID: 11762613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Molecular diagnosis of chronic myeloproliferative diseases and myelodysplastic syndromes].
    Bock O
    Verh Dtsch Ges Pathol; 2007; 91():140-53. PubMed ID: 18314608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Flow cytometric diagnosis of myelodysplasia and myeloproliferative disorders.
    Wood BL
    J Biol Regul Homeost Agents; 2004; 18(2):141-5. PubMed ID: 15471218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders.
    Valent P
    Blood Rev; 2009 Jul; 23(4):157-65. PubMed ID: 19246139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hematologic disorders affecting the lungs.
    Edwards JR; Matthay KK
    Clin Chest Med; 1989 Dec; 10(4):723-46. PubMed ID: 2689072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Significance, diagnosis and prognosis in the cytogenetic analysis in acute leukemias and myelodysplastic syndromes].
    Jotterand Bellomo M
    Ther Umsch; 1996 Feb; 53(2):103-10. PubMed ID: 8629259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [10 years' experiences with flow cytometric immunological phenotyping in malignant hematologic diseases].
    Kristensen JS; Hokland P
    Ugeskr Laeger; 1996 Oct; 158(43):6098-102. PubMed ID: 8928296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cytochemical methods in hematology].
    Plüss HJ
    Schweiz Med Wochenschr; 1971 Oct; 101(42):1500-6. PubMed ID: 4336703
    [No Abstract]   [Full Text] [Related]  

  • 37. Acute erythroid neoplastic proliferations. A biological study based on 62 patients.
    Domingo-Claros A; Larriba I; Rozman M; Irriguible D; Vallespí T; Aventin A; Ayats R; Millá F; Solé F; Florensa L; Gallart M; Tuset E; Lopez C; Woessner S
    Haematologica; 2002 Feb; 87(2):148-53. PubMed ID: 11836165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduction in multi-lineage and erythroid progenitors distinguishes myelodysplastic syndromes from non-malignant cytopenias.
    Vercauteren SM; Bashashati A; Wu D; Brinkman RR; Eaves C; Eaves A; Karsan A
    Leuk Res; 2009 Dec; 33(12):1636-42. PubMed ID: 19414193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
    Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
    Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Salient features of hematological diseases.
    Fey MF
    Ann Oncol; 2007 Jan; 18 Suppl 1():i54-i64. PubMed ID: 17311824
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.